Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?

被引：2
|
作者：
Fabi, A [1 ]
Ferretti, G [1 ]
Salesi, N [1 ]
Papaldo, P [1 ]
Carlini, P [1 ]
Ciccarese, M [1 ]
Di Cocco, B [1 ]
Cecere, F [1 ]
Nardoni, C [1 ]
Felici, A [1 ]
Cognetti, F [1 ]
机构：
[1] Regina Elena Inst Canc Res, Div Med Oncol A, I-00144 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷 / 03期
关键词：
D O I：
10.1093/annonc/mdi078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [41] Rates of HER2 overexpression and trastuzumab response in Caribbean women with breast cancer
    Feng, Qi
    Dietz, Donald Elmore
    Sidhu, Gurinder Singh
    Axiotis, Constantine A.
    Braverman, Albert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Phase II study of pegylated liposomal doxorubicin (PLD) and carboplatin (Cb) can be administered with trastuzumab (H) in patients with metastatic breast cancer.
    Collea, R. P.
    Kruter, F. W.
    Cantrell, J. E.
    George, T. K.
    Kruger, S.
    Favret, A. M.
    Lindquist, D. L.
    Melnyk, A. M., Jr.
    Pluenneke, R. E.
    Shao, S. H.
    Crockett, M. W.
    Asmar, L.
    O'Shaughnessy, J. A.
    CANCER RESEARCH, 2009, 69 (02) : 383S - 383S
  • [43] Preoperative Therapy with Pegylated Liposomal Doxorubicin, Cisplatin and Infusional Fluoruracil plus Trastuzumab (±Endocrine Therapy) in Locally Advanced HER2 Positive Breast Cancer
    Torrisi, R.
    Dellapasqua, S.
    Cancello, G.
    Balduzzi, A.
    Montagna, E.
    Ghisini, R.
    Iorfida, M.
    Veronesi, P.
    Viale, G.
    Goldhirsch, A.
    Colleoni, M.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [44] Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin
    Liwei Meng
    Liming Huang
    Yingchun Xu
    Wei Zhang
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 3 - 7
  • [45] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [46] Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin
    Meng, Liwei
    Huang, Liming
    Xu, Yingchun
    Zhang, Wei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 3 - 7
  • [47] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [48] A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.
    Rocca, Andrea
    Cecconetto, Lorenzo
    Passardi, Alessandro
    Melegari, Elisabetta
    Andreis, Daniele
    Monti, Manuela
    Maltoni, Roberta
    Sarti, Samanta
    Pietri, Elisabetta
    Schirone, Alessio
    Fedeli, Anna
    Donati, Caterina
    Nanni, Oriana
    Amadori, Dino
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [50] Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel as first line therapy in metastatic breast cancer
    Fulfaro, F.
    Valerio, M. R.
    Cicero, G.
    Rinaldi, G.
    Intrivici, C.
    Pizzo, T.
    Crosta, A.
    Scibilia, C.
    Gebbia, N.
    ANNALS OF ONCOLOGY, 2006, 17 : XI10 - XI11
12345